BlackRock’s Co-Diagnostics CODX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-14,248
Closed -$72.1K 5706
2025
Q4
$72.1K Hold
14,248
﹤0.01% 4975
2025
Q3
$147K Hold
14,248
﹤0.01% 4746
2025
Q2
$120K Sell
14,248
-2,512
-15% -$23.5K ﹤0.01% 4797
2025
Q1
$156K Sell
16,760
-48
-0.3% -$917 ﹤0.01% 4650
2024
Q4
$378K Sell
16,808
-5
-0% -$158 ﹤0.01% 4491
2024
Q3
$630K Buy
16,813
+79
+0.5% +$3.03K ﹤0.01% 4277
2024
Q2
$628K Buy
16,734
+66
+0.4% +$2.4K ﹤0.01% 4286
2024
Q1
$560K Sell
16,668
-60
-0.4% -$2.17K ﹤0.01% 4343
2023
Q4
$667K Sell
16,728
-29
-0.2% -$1.02K ﹤0.01% 4357
2023
Q3
$533K Sell
16,757
-127
-0.8% -$4.8K ﹤0.01% 4406
2023
Q2
$562K Buy
16,884
+164
+1% +$6.28K ﹤0.01% 4452
2023
Q1
$742K Sell
16,720
-1,251
-7% -$100K ﹤0.01% 4432
2022
Q4
$1.36M Sell
17,971
-16
-0.1% -$1.5K ﹤0.01% 4302
2022
Q3
$1.73M Buy
17,987
+1,266
+8% +$177K ﹤0.01% 4265
2022
Q2
$2.81M Buy
16,721
+472
+3% +$71.8K ﹤0.01% 4082
2022
Q1
$3.01M Sell
16,249
-99
-0.6% -$20.5K ﹤0.01% 4215
2021
Q4
$4.38M Sell
16,348
-1,361
-8% -$357K ﹤0.01% 4050
2021
Q3
$5.17M Buy
17,709
+444
+3% +$130K ﹤0.01% 3943
2021
Q2
$4.27M Sell
17,265
-47,904
-74% -$12.3M ﹤0.01% 3941
2021
Q1
$18.7M Buy
65,169
+1,113
+2% +$444K ﹤0.01% 3224
2020
Q4
$17.9M Buy
64,056
+3,992
+7% +$1.48M ﹤0.01% 3065
2020
Q3
$24.5M Buy
60,064
+4
+0% +$2.06K ﹤0.01% 2749
2020
Q2
$34.9M Buy
+60,060
New +$27.4M ﹤0.01% 2462
2018
Q2
Sell
-43
Closed -$3K 5018
2018
Q1
$3K Buy
+43
New +$3.28K ﹤0.01% 4767

Other funds holding CODX

BlackRock's CODX Position: Q1 2026 in Review

BlackRock sold out of Co-Diagnostics (CODX) in Q1 2026, closing a stake of 14,248 shares — an estimated $72.1K sold.

BlackRock first reported a position in CODX in Q1 2018 and held it in 24 quarters. The position peaked at $34.9M in Q2 2020. 14 funds tracked by Wall St. Rank hold CODX as of Q1 2026.

  • BlackRock reported no remaining Co-Diagnostics position as of Q1 2026 after selling out during the quarter.
  • BlackRock sold 14,248 Co-Diagnostics shares in Q1 2026, an estimated $72.1K.
  • BlackRock first reported a position in Co-Diagnostics in Q1 2018 and held it in 24 quarters.
  • BlackRock's Co-Diagnostics position peaked at $34.9M in Q2 2020.
  • 14 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.